The new RCT will compare randomised results from 120 cycles of the most challenging IVF patients, women from 38 to 40 years and men with severe oligozoospermia, in which 24 sure PGS is used to select embryos for implantation against 120 cycles in which PGS is not applied.
Announcing the study, Dr Carlos Simon, Professor of Obstetrics and Gynaecology at the University of Valencia and Scientific Director of IVI Foundation since 1994 confirmed, “We have already submitted for publication RCT data which showed an increase in ongoing pregnancy per transfer from 18.9% to 42.8% when 9 chromosome PGS FISH was used in the treatment of our more difficult cases such as advanced maternal age and implantation failure. With rapid techniques for screening all 24 chromosomes now available we expect this number to increase further. We do however believe it is important that this is confirmed by RCT in order to understand how many of the 25,000 IVF cycles performed at IVI each year might ultimately benefit from this exciting new approach”.
Commenting on the study, Dr Nick Haan, CEO of BlueGnome, explained, “We have just seen remarkable results from the publication of the first RCT into the application of 24sure to blastocysts biopsies taken on day 5 and are now well advanced with a much larger, multi-centre, RCT being undertaken by ESHRE using polar body biopsy. We were therefore particularly keen to work with Professor Simon and his team who are world leaders in reproductive medicine and the biopsy of single blastomeres on day 3. We believe that comparison of such a comprehensive set of RCT results, all generated on the same 24sure platform, will enable us to fully understand the benefits of offering 24 chromosome PGS screening as the default standard of care for all IVF cycles.”
About IVI
The Valencian Infertility Institute was founded in 1990 as the first Spanish medical institution entirely specialized in human reproduction. At present it has 20 clinics in 8 countries around the world and is considered as the European institution leader in reproductive medicine.
About BlueGnome
BlueGnome is a leading provider of genetic solutions for the screening of chromosomal abnormalities in cytogenetics and IVF www.cambridgebluegnome.com www.24suretest.com
Follow BlueGnomeLtd on twitter
BlueGnome microarrays are for research use only.
*******
For further information please contact:
Dr. Sally Cartwright, Marketing Manager
Sally.Cartwright@cambridgebluegnome.com
+44 (0) 1223 885900
____________________________________________